Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
A larger percentage of participants receiving CBT plus amitriptyline reached a 50% reduction in migraine frequency during treatment compared with HE plus amitriptyline.
Recovery time varies depending on which class of medication the patient is overusing.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Neurology Advisor Articles
- Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence
- Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease
- MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics
- Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability
- The Handoff: Your Week in Neurology News - 9/21/17
- Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease
- Cognitive Decline Related to Site Specific Mid-Life Adiposity
- Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline
- Higher Doses of Pregabalin for Neuropathic Pain: Is it Safe?
- Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus
- Zika Virus Associated With High Risk for Neurologic Complications in Adults
- Evolocumab Has No Effect on Cognition in Patients Attaining Very Low Levels of LDL Cholesterol
- Acute Oxygen Therapy for Cluster Headahce Not Prohibitively Expensive
- β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD
- Little Evidence to Support Doctor, Patient Electronic Communication Guidelines